These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23138905)

  • 41. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs.
    Wehner NG; Shopp G; Rocca MS; Clarke J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):98-107. PubMed ID: 19294679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys.
    Moriyama T; Kakiuchi D; Grasso L; Hutto DL; Fernando D; Schweizer C
    Reprod Toxicol; 2018 Aug; 79():89-95. PubMed ID: 29928988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.
    Zorbas M; Hurst S; Shelton D; Evans M; Finco D; Butt M
    Regul Toxicol Pharmacol; 2011 Mar; 59(2):334-42. PubMed ID: 21130822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Teratology testing under REACH.
    Barton S
    Methods Mol Biol; 2013; 947():57-72. PubMed ID: 23138895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?
    Baldrick P
    Regul Toxicol Pharmacol; 2011 Mar; 59(2):227-36. PubMed ID: 20937341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Teratology studies in the mouse.
    Marsden E; Leroy M
    Methods Mol Biol; 2013; 947():111-23. PubMed ID: 23138900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introduction to special issue on developmental and reproductive toxicity study designs for pharmaceuticals.
    Wise LD
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):417. PubMed ID: 20025037
    [No Abstract]   [Full Text] [Related]  

  • 48. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats.
    Weisenburger WP; Hagler AR; Tassinari MS
    Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):171-84. PubMed ID: 15282738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the bioeffects of prenatal ultrasound exposure in the cynomolgus macaque (Macaca fascicularis): II. Growth and behavior during the first year.
    Tarantal AF; Hendrickx AG
    Teratology; 1989 Feb; 39(2):149-62. PubMed ID: 2648635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The teratology testing of cosmetics.
    Spézia F; Barrow PC
    Methods Mol Biol; 2013; 947():91-4. PubMed ID: 23138898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In honor of the Teratology Society's 50th anniversary: The role of Teratology Society members in the development and evolution of in vivo developmental toxicity test guidelines.
    Tyl RW
    Birth Defects Res C Embryo Today; 2010 Jun; 90(2):99-102. PubMed ID: 20544693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development.
    Campion SN; Bowman CJ; Cappon GD; Harrison A; Finch GL; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2012 Jun; 95(3):250-61. PubMed ID: 22495820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation and characterization of monkey embryonic stem cells.
    Suemori H; Nakatsuji N
    Methods Mol Biol; 2006; 329():81-9. PubMed ID: 16845985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The teratology testing of food additives.
    Barrow PC; Spézia F
    Methods Mol Biol; 2013; 947():73-80. PubMed ID: 23138896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals.
    Rocca M; Morford LL; Blanset DL; Halpern WG; Cavagnaro J; Bowman CJ
    Regul Toxicol Pharmacol; 2018 Oct; 98():69-79. PubMed ID: 30009863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vitrification and transfer of cynomolgus monkey (Macaca fascicularis) embryos fertilized by intracytoplasmic sperm injection.
    Yamasaki J; Iwatani C; Tsuchiya H; Okahara J; Sankai T; Torii R
    Theriogenology; 2011 Jul; 76(1):33-8. PubMed ID: 21529920
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the bioeffects of prenatal ultrasound exposure in the cynomolgus macaque (Macaca fascicularis): III. Developmental and hematologic studies.
    Tarantal AF; O'Brien WD; Hendrickx AG
    Teratology; 1993 Feb; 47(2):159-70. PubMed ID: 8446929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.